FIDELIO-DKD: Finerenone in Subjects with Type 2 Diabetes Mellitus and Diabetic Kidney Disease

FIDELIO-DKD: Finerenone in Subjects with Type 2 Diabetes Mellitus and Diabetic Kidney Disease

Rationale : Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist,
reduced albuminuria in patients with type 2 DM. Long term efficacy and safety in terms
of renal and cardiovascular outcomes remains unknown.

Infographic

Reference

Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G; FIDELIO-DKD Investigators. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020 Dec 3;383(23):2219-2229.

>